Sasanlimab maintenance for bladder cancer after chemotherapy
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if sasanlimab, an immunotherapy drug, can help prevent bladder cancer from coming back after initial chemotherapy and before bladder removal surgery. It is for people with muscle-invasive bladder cancer that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have muscle-invasive bladder cancer that hasn't spread beyond the bladder.
- You are able to get chemotherapy with gemcitabine and cisplatin before surgery.
- You have not had chemotherapy for this cancer before.
- You are in generally good health (able to do daily activities) and have adequate organ function.
- You are at least 18 years old.
- You are willing to use highly effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy, immunotherapy, and radiation to treat muscle-invasive bladder cancer while trying to avoid bladder removal. It compares this approach to a watch-and-wait strategy, and also looks at adding maintenance immunotherapy.
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
This trial looks at how the immune environment around a muscle-invasive bladder tumor changes after you receive treatment before surgery (neoadjuvant therapy). The goal is to understand why some tumors respond better, which could help guide future treatments.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a combination of two drugs, sacituzumab govitecan and zimberelimab, to treat muscle-invasive bladder cancer without removing the bladder. It's for patients who cannot or choose not to have bladder removal surgery or standard chemotherapy.
Hear when a new MIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.